Cefazolin

Lore & Background

It is on the World Health Organization's List of Essential Medicines and is available as a generic medication. It was originally developed by Fujisawa Pharmaceutical and marketed under names like Cefamezin, with Kefzol being a common brand by Eli Lilly. Other common trade names include Ancef and Zolicef.

Reader's Guide

Cefazolin is a first-generation cephalosporin antibiotic that works by interfering with the bacteria's cell wall, making it bactericidal. It is active against many gram-positive bacteria, including methicillin-susceptible Staphylococcus aureus, and some gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae. It is not effective against methicillin-resistant Staphylococcus aureus, Enterococcus, anaerobic bacteria, or atypical bacteria like Mycoplasma and Chlamydia. Historically thought to be contraindicated in patients with penicillin allergies, several recent studies have refuted this, and it is proven safe in almost all patients, though a small chance of cross-reactivity remains. Common side effects include diarrhea, vomiting, yeast infections, and allergic reactions. It is relatively safe for use during pregnancy and breastfeeding, and is often the preferred drug for surgical prophylaxis. Cefazolin does not penetrate the central nervous system and is therefore not effective in treating meningitis.

Did You Know?

• It is on the World Health Organization's List of Essential Medicines.
• Cefazolin is not effective against methicillin-resistant Staphylococcus aureus (MRSA).
• It is often the preferred drug for surgical prophylaxis.

Therapeutic Reach and Spectral Boundaries

Cefazolin occupies a distinctive niche in the antibiotic arsenal as a first-generation cephalosporin whose activity is concentrated against gram-positive organisms while extending partially into certain gram-negative species. Clinicians deploy it intramuscularly or intravenously to combat a wide array of infections, including cellulitis, urinary tract and respiratory infections, pneumonia, endocarditis, bone and joint infections, biliary tract infections, genital infections, and even life-threatening sepsis. Its role in surgical prophylaxis is particularly prominent, as it is frequently the preferred agent for preventing post-operative infections. It also serves as a prophylactic against group B streptococcal disease in the perinatal period. However, its spectrum has clear boundaries: it cannot penetrate the central nervous system, rendering it useless against meningitis, and it is ineffective against MRSA, Enterococcus, anaerobic bacteria, atypical organisms such as Mycoplasma and Chlamydia, Pseudomonas, Serratia, and Listeria. Among susceptible organisms, it handles methicillin-susceptible S. aureus, various streptococci, E. coli, Proteus mirabilis, and Klebsiella pneumoniae.

Molecular Mechanism: Lethal Disruption of the Cell Wall

At the molecular level, cefazolin exerts its lethal effect by targeting the bacterial cell wall. It binds to penicillin-binding proteins, which are the enzymes responsible for catalyzing the final stages of peptidoglycan synthesis. These proteins normally remove D-alanine from the peptidoglycan precursor, a critical step in assembling the structural mesh that gives bacteria their shape and integrity. By blocking this process, cefazolin prevents new cell wall material from being laid down. Because bacteria simultaneously and continuously degrade their existing cell walls, the inability to replace the lost material leads to osmotic instability and ultimately lysis. This makes cefazolin a true bactericidal agent rather than merely bacteriostatic. A key pharmacological advantage over older penicillins is its enhanced stability against many bacterial beta-lactamases, the enzymes that typically destroy penicillin molecules. This improved resistance to enzymatic degradation is what grants first-generation cephalosporins like cefazolin their broader and more reliable activity against beta-lactamase-producing strains of Staphylococcus aureus and other susceptible organisms.

Safety Landscape and Special Populations

The tolerability profile of cefazolin is generally favorable, with the most frequently reported adverse effects being diarrhea, nausea, vomiting, abdominal discomfort, and skin rash, all occurring in one to ten percent of patients. Less commonly, users may experience dizziness, headache, fatigue, pruritus, or transient hepatitis. A historically significant concern was cross-reactivity in penicillin-allergic patients; for years, cefazolin was considered contraindicated in such individuals. However, multiple recent studies have demonstrated that it is safe for the vast majority of penicillin-allergic patients, though close monitoring remains prudent given the structural similarity between the two drug classes. In pregnancy, cefazolin carries a category B designation, and it is specifically recommended as an alternative for GBS prophylaxis in penicillin-allergic women without an anaphylaxis history. A small quantity does pass into breast milk, warranting caution during lactation. No safety data exist for premature neonates. Patients with renal impairment or those on hemodialysis may require dose adjustments, while hepatic disease does not significantly alter drug levels. The N-methylthiodiazole side-chain, released during metabolism, can cause hypoprothrombinemia and a disulfiram-like reaction with alcohol.

From Patent to Global Essential: A Legacy of Access

Cefazolin's journey from laboratory compound to a cornerstone of global infectious-disease treatment spans just a few years of intense development. Its inclusion on the World Health Organization's List of Essential Medicines underscores the organization's recognition of cefazolin as a drug that should be available in every health system, regardless of income level. Today it is widely manufactured and distributed as a generic product, making it accessible in settings where branded antibiotics would be prohibitively expensive. This broad availability has cemented its role not only as a treatment for susceptible bacterial infections but also as the preferred prophylactic in operating theaters. For patients with staphylococcal bacteremia who cannot tolerate penicillin, cefazolin offers a well-established alternative, bridging the gap between efficacy and safety in a way that has shaped clinical practice for over five decades.